MRTX - Mirati Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

41.14

-1.44 (-3.38%)

At close: 4:00PM EDT

41.14 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	42.58
Open	42.20
Bid	38.85 x 800
Ask	45.00 x 800
Day's Range	40.45 - 43.41
52 Week Range	12.26 - 65.35
Volume	431,221
Avg. Volume	490,807

Market Cap	1.331B
Beta (3Y Monthly)	2.91
PE Ratio (TTM)	N/A
EPS (TTM)	-2.78
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	57.89

Trade prices are not sourced from all markets

All

News

Press Releases

PR Newswire28 minutes ago
Mirati Therapeutics To Provide Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress And Conduct Investor Call
- Two oral presentations will feature updated clinical data from an ongoing phase 2 clinical trial of sitravatinib in combination with nivolumab and a Phase 1b clinical trial of sitravatinib as a single ...
Motley Fool6 days ago
3 Biotech Stocks With Major Incoming Catalysts
These three biotechs will soon present clinical trial results that could send their share prices screaming in one direction or the other.
Zacks7 days ago
Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy
2018 Nobel Prize for medicine was awarded for immunotherapy research. Here is what investors need to know about stocks and ETF focused on this innovative area.
Simply Wall St.last month
Mirati Therapeutics Inc (NASDAQ:MRTX): Time For A Financial Health Check
The direct benefit for Mirati Therapeutics Inc (NASDAQ:MRTX), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-offRead More...
Market Realistlast month
Why Endocyte’s Stock Price Rose 11.4% Yesterday
Today, Endocyte stock is trading at $19.16, which reflects ~1.43% growth from yesterday’s closing price of $18.89. Yesterday, the stock price grew ~11.38% to reach $18.89, versus its close of $16.96 the day before. Endocyte hit a 52-week high of $20.85 on September 4. It hit a 52-week low of $1.36 on September 28, 2017. Reason for growth
PR Newswire2 months ago
Mirati Therapeutics To Participate In Oncology Panels At The 2018 Citi Biotech Conference
SAN DIEGO , Aug. 29, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in two panel discussions, at the 2018 Citi Biotech Conference ...
Zacks2 months ago
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?
Style Box ETF report for DWAS
PR Newswire2 months ago
Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition
SAN DIEGO, Aug. 16, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical stage targeted oncology company, today announced that a KRAS G12C poster will be presented by scientists from Mirati and Array BioPharma at the 255th American Chemical Society (ACS) National Meeting & Exposition being held in Boston, MA, August 19-23, 2018. "We are looking forward to the first public presentation of our orally-active series of covalent inhibitors of KRAS G12C.
Associated Press2 months ago
Mirati: 2Q Earnings Snapshot
The San Diego-based company said it had a loss of 94 cents per share. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...
PR Newswire2 months ago
Mirati Therapeutics Reports Second Quarter Financial Results
SAN DIEGO , Aug. 1, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter ended June 30, 2018 ...
Motley Fool3 months ago
How to Invest in Clinical-Stage Biotechs Without Losing Money
Clinical-stage biotechs can wreak havoc on your portfolio. Here's one approach that can limit the potential damage while still allowing you to take a long-term approach to capital appreciation.
PR Newswire3 months ago
Mirati Therapeutics To Present Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress
SAN DIEGO , July 24, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that two abstracts highlighting data from ongoing clinical ...
ACCESSWIRE3 months ago
Breakfast Technical Briefing on Mirati Therapeutics and Three Other Additional Biotech Stocks
Stock Research Monitor: KTOV, LOXO, and MDGL LONDON, UK / ACCESSWIRE / July 17, 2018/ If you want a free Stock Review on MRTX sign up now at www.wallstequities.com/registration . Today, WallStEquities.com ...
PR Newswire4 months ago
Mirati Therapeutics Added to Russell 2000® Index
SAN DIEGO, June 25, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical-stage targeted oncology company, today announced that it has been added to the Russell 2000® Index, effective as of the open of the market on Monday, June 25, 2018, following Russell's annual reconstitution of its comprehensive set of U.S. and global equity indexes. The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market. The index is a subset of the Russell 3000® Index and represents approximately 10 percent of the total market capitalization of that index.
Zacks4 months ago
Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?
Style Box ETF report for DWAS
PR Newswire4 months ago
Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO , June 11, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the closing of its previously announced underwritten public offering of 3,162,500 shares of its common ...
Motley Fool4 months ago
Here's Why Mirati Therapeutics, Inc. Is Rising Today
Wall Street cheers after the company announced favorable terms from a just-announced capital raise. Here's what investors need to know.
PR Newswire4 months ago
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
SAN DIEGO, June 7, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced the pricing of an underwritten public offering of 2,750,000 shares of its common stock at a price to the public of $38.85 per share. In addition, and in lieu of common stock, Mirati is offering to certain investors pre-funded warrants to purchase up to an aggregate of 421,650 shares of common stock at a purchase price of $38.849 per warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $123.2 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati.
PR Newswire4 months ago
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO, June 6, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock. Mirati expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares are being offered by Mirati.
PR Newswire5 months ago
Mirati To Present New Data In Renal Cell Carcinoma From Ongoing Phase 1b Clinical Trial Of Single Agent Sitravatinib At The 2018 ASCO Annual Meeting
SAN DIEGO , May 31, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced that new data from the ongoing Phase 1b clinical trial of single ...
PR Newswire5 months ago
Mirati Therapeutics To Present At Jefferies 2018 Global Healthcare Conference
SAN DIEGO , May 30, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the Jefferies Annual Global Healthcare Conference in New York ...
Zacks5 months ago
Mirati Therapeutics (MRTX) Soars: Stock Adds 13.6% in Session
Mirati Therapeutics (MRTX) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes.
Associated Press5 months ago
Mirati: 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 51 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
PR Newswire5 months ago
Mirati Therapeutics Reports First Quarter Financial Results
SAN DIEGO , May 7, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage oncology company, today reported financial results for the first quarter ended March 31, 2018 . "We ...